Skip to content
PICO Portalanswers from OpenAlex

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

PaperCitations, authors & open-access status

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is a paper indexed in PICO Portal from OpenAlex.

How many citations does High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease have?

PICO Portalcitation count

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease has 16 citations in the OpenAlex counts PICO Portal stores.

When was High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease published?

PICO Portalyear

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease has 2018 year in the PICO Portal index.

What is the open-access status of High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?

PICO Portaloa status

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease has closed oa status in the PICO Portal index.

What is the DOI of High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?

PICO Portaldoi

The DOI for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is on the source record.

What is the PMID of High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?

PICO Portalpmid

The PMID for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is on the source record.

What is the OpenAlex record for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease?

PICO Portalopenalex

The OpenAlex for High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial